Beiersdorf unveils Thiamidol NPD via Eucerin brand and enters post-acne marks arena

18 Aug 2021 --- Personal care behemoth Beiersdorf is breaking into the post-acne marks market via its dermocosmetics brand Eucerin and the global launch of two products from its Dermopure series for acne-prone skin.

The combination of the products – Eucerin Dermopure Triple Effect Serum with Thiamidol and the Eucerin Dermopure Protective Fluid SPF 30 – offers an effective solution to reduce and prevent post-acne marks and blemishes, and to control shine.

“The serum contains a unique and patented active ingredient, Thiamidol, which counteracts and reverses hyperpigmentation by addressing the root cause: the formation of melanin in the skin. In a 10-year scientific project, Beiersdorf examined and tested more than 50,000 possible ingredients. Thiamidol emerged as the winning ingredient and has now proven itself over many years of life-changing efficacy,” Patrick Rasquinet, member of the executive board for pharmacy and selective brands at Beiersdorf, tells PersonalCareInsights.

“The launch is relevant to the C.A.R.E.+ company strategy pillar ‘Winning with Skincare,’” he notes.

“By focusing on post-acne marks, we are entering a completely new market. This skin condition affects many people worldwide, with a severe impact on their psychological well-being. Our effective dermocosmetic solutions offer great potential to meet the correspondingly high demand of our consumers,” Rasquinet says.

Thiamidol for the skin
One special feature is the use of the patented active ingredient Thiamidol in the new serum.

“With Thiamidol, we have achieved the leading position in the Even Skin market in 23 countries,” says Cornelius Becker, global head of derma for Beiersdorf.

“Now, for the first time, we were able to bring Thiamidol into the Acne category, thus continuing the success story of our life-changing ingredient also for blemish-prone skin.”

The combination of the Eucerin products can reduce and prevent post-acne marks and blemishes.Acne affects up to 95 percent of adolescents and 40 percent of adults. Many of those affected experience post-inflammatory hyperpigmentation (PIH), also known as post-acne marks, which can persist for five years or even longer after the acute acne has vanished, the company says.

The widespread phenomenon of PIH is shown to negatively influence self-esteem and quality of life, according to the company.

The new product combination from the Eucerin Dermopure series provides effective relief from the physical and emotional burden of blemish-prone skin with post-acne marks.

Rasquinet explains: “Acne leaves not only marks on the skin but also emotional scars. That is why the effects of our product innovations go more than just skin-deep, a philosophy also expressed in the Eucerin brand purpose.”

How the products work
The root cause of PIH is increased melanin production, which is stimulated by inflammatory factors.

The blemish triggers melanocytes – the melanin-producing cells – to release excessive pigment granules. These darken and discolor the formerly stressed area.

The Eucerin Dermopure Triple Effect Serum contains Thiamidol, which counteracts and reverses hyperpigmentation by addressing the root cause: the formation of melanin in the skin.

Furthermore, the formulation contains salicylic acid to reduce blemishes and licochalcone A to prevent new blemishes from appearing. Thanks to sebum-regulation technology, it leaves the skin with a long-lasting matte look.

Eucerin Dermopure Protective Fluid SPF 30 helps protect post-acne marks from darkening due to sun exposure. It contains effective filters to block ultraviolet rays (A and B), with a sun protection factor (SPF) of 30.

Antibacterial decanediol helps prevent blemishes, and licochalcone A soothes irritated skin. The formula also features sebum-regulation technology for a long-lasting matte appearance. The products have enhanced efficacy when used in combination, Beiersdorf notes.

By Kristiana Lalou

To contact our editorial team please email us at editorial@cnsmedia.com